Educational Resources

ACCC Digital Patient Assistance & Reimbursement Guide

A Phase 3 Study of elacestrant versus standard endocrine therapy in node-positive ER+, HER2- early breast cancer with high risk of recurrence (ELEGANT)

Published on: 10/22/2025 Stemline Logo

Despite advances in the adjuvant treatment of early-stage estrogen receptor-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer, there continues to be a risk of recurrence. The ELEGANT study is a Global, Multicenter, Randomized, Open-label Phase 3 Study with the primary goal to evaluate the efficacy and safety of elacestrant versus standard endocrine therapy in participants with node-positive ER+/HER2- early breast cancer with high risk of recurrence. The main purpose of this study is to compare the Invasive Breast Cancer-Free Survival (IBCFS) over a period of up to 5 years. 4220 participants will be included in this study around the world. Participants will have equal chance to be assigned to receive either of the treatment combinations.

More info: Study Details | Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence (ELEGANT) | ClinicalTrials.gov. Or visit elegantstudy.com and/or scan QR code below:

Anemia in Focus: The Challenge of Identifying Myelodysplastic Syndromes (MDS)

Published on: February 17, 2025

Watch Dr. David Sallman, a leading MDS specialist at the Moffitt Cancer Center, talk about the importance of investigating unexplained anemia.

View Resource

Help Patients Face the Realities of Life with Metastatic Breast Cancer Through Expose MBC

Published on: July 15, 2024

Gilead Oncology understands that metastatic breast cancer (MBC) is different from early breast cancer in many ways. Expose MBC is a platform for patients and their caregivers, friends, and family to share and gain honest information about their experiences, as well as to find resources, support, and community to help live their unique reality.

Visit http://Expose-MBC.com and share this site with your patients.

ESR1 Mutations in ER+/HER2 - Metastatic Breast Cancer

Published on: June 26, 2024

Nearly 1 out of 2 people with ER+/HER2- metastatic breast cancer may develop an ESR1 mutation after progression on hormone therapy.

Learn more about this ESR1 mutation at http://Knowesr1.com.

Diagnosis and Treatment of Hematologic Cancer

Published on: June 26, 2024

BPDCN is a cancer that affects your blood and the soft tissue inside your bones, which is called bone marrow. It can also affect other parts of your body, such as your lymph nodes, spleen, central nervous system, and skin.

Learn more about this ESR1 mutation at https://BPDCNinfo.com.

PharmaEssentia Educational Resource

PharmaEssentia SOURCE helps connect patients to ongoing support, education, and resources throughout their treatment journey.

Navigating insurance and financial hurdles
Educating about treatment initiation, including injection training
Offering ongoing patient engagement and resources

Click here to enroll in SOURCE.

Click here for our copay assistance program.